Key points from article :
Injectable hydrogel aims to repair damage and restore cardiac function in heart failure patients.
Hydrogel is made from the natural scaffolding of cardiac muscle tissue.
VentriGel can be safely injected into patients who had suffered a heart attack in the past 2 to 36 months.
Once injected, VentriGel forms a scaffold that acts as a reparative environment where healthy cells migrate.
Future phase 2 clinical trial will evaluate how effectively VentriGel can improve cardiac function.
Findings were published in the Journal of the American College of Cardiology.
Phase 1 clinical trial is done by the Ventrix, a spin-off company of University of California.
